EPS for AcelRx Pharmaceuticals, Inc. (ACRX) Expected At $-0.21; Ingersoll-Rand Plc (IR) Had 12 Bulls

February 14, 2018 - By Adrian Mccoy

Among 22 analysts covering Ingersoll-Rand Plc (NYSE:IR), 12 have Buy rating, 0 Sell and 10 Hold. Therefore 55% are positive. Ingersoll-Rand Plc had 69 analyst reports since July 30, 2015 according to SRatingsIntel. Stifel Nicolaus maintained the stock with “Buy” rating in Wednesday, July 5 report. Stifel Nicolaus maintained Ingersoll-Rand Plc (NYSE:IR) on Thursday, October 26 with “Buy” rating. As per Thursday, April 27, the company rating was maintained by RBC Capital Markets. Susquehanna maintained Ingersoll-Rand Plc (NYSE:IR) on Thursday, February 1 with “Hold” rating. CLSA downgraded the stock to “Outperform” rating in Monday, April 4 report. The stock of Ingersoll-Rand Plc (NYSE:IR) earned “Hold” rating by Robert W. Baird on Wednesday, November 15. The rating was maintained by Stifel Nicolaus on Monday, September 11 with “Buy”. The rating was maintained by Robert W. Baird with “Hold” on Wednesday, August 23. The firm has “Sector Perform” rating by RBC Capital Markets given on Thursday, October 27. As per Monday, March 20, the company rating was upgraded by Wells Fargo. See Ingersoll-Rand Plc (NYSE:IR) latest ratings:

01/02/2018 Broker: BMO Capital Markets Rating: Buy New Target: $115.0 Maintain
01/02/2018 Broker: Susquehanna Rating: Hold New Target: $94.0 Maintain
31/01/2018 Broker: Robert W. Baird Rating: Hold New Target: $104.0 Maintain
31/01/2018 Broker: Stifel Nicolaus Rating: Buy New Target: $112.0 Maintain
31/01/2018 Broker: RBC Capital Markets Rating: Hold New Target: $98.0 Maintain
23/01/2018 Broker: UBS Rating: Buy Initiates Coverage On
12/01/2018 Broker: Susquehanna Rating: Hold New Target: $92.0 Maintain
03/01/2018 Broker: RBC Capital Markets Rating: Hold New Target: $95.0 Maintain
08/12/2017 Broker: Goldman Sachs Old Rating: Neutral New Rating: Buy Upgrade
15/11/2017 Broker: Robert W. Baird Rating: Hold New Target: $98.0 Maintain




Analysts expect AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) to report $-0.21 EPS on March, 1.They anticipate $0.00 EPS change or 0.00% from last quarter’s $-0.21 EPS. After having $-0.28 EPS previously, AcelRx Pharmaceuticals, Inc.’s analysts see -25.00% EPS growth. The stock increased 1.45% or $0.02 during the last trading session, reaching $1.75. About 24,045 shares traded. AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) has declined 14.24% since February 14, 2017 and is downtrending. It has underperformed by 30.94% the S&P500.

Investors sentiment decreased to 0.7 in 2017 Q3. Its down 0.05, from 0.75 in 2017Q2. It fall, as 12 investors sold AcelRx Pharmaceuticals, Inc. shares while 15 reduced holdings. 8 funds opened positions while 11 raised stakes. 6.65 million shares or 37.02% less from 10.56 million shares in 2017Q2 were reported. Geller Family Office Ltd Liability Corp reported 0.23% in AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX). Palo Alto Ltd Liability Co stated it has 0.2% in AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX). Two Sigma Securities Ltd Liability holds 0.01% of its portfolio in AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) for 17,073 shares. Goldman Sachs owns 648 shares for 0% of their portfolio. Bnp Paribas Arbitrage holds 8 shares. Manufacturers Life The invested 0% of its portfolio in AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX). 56,473 were reported by Barclays Public Limited Co. Raymond James And Assocs reported 46,000 shares stake. Northern Trust Corporation holds 54,829 shares. Comml Bank Of America Corp De holds 0% in AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) or 3,300 shares. Vanguard Gru invested in 1.38M shares. 22,800 were reported by Williams Jones Associates Ltd Llc. Fincl Bank Of New York Mellon holds 0% or 67,961 shares. Susquehanna Group Llp reported 226,288 shares. Creative Planning reported 0% of its portfolio in AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX).

Since October 2, 2017, it had 0 insider buys, and 1 insider sale for $53,752 activity. Hamel Lawrence G sold $53,752 worth of AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) on Monday, October 2.

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. The company has market cap of $88.09 million. The Company’s lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet, which is in Phase III clinical trial for the treatment of moderate-to-severe acute pain. It currently has negative earnings. The company's late-stage investigational product candidate is Zalviso, a pre-programmed and patient-controlled analgesia device that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain.

Among 8 analysts covering AcelRx Pharmaceuticals (NASDAQ:ACRX), 5 have Buy rating, 0 Sell and 3 Hold. Therefore 63% are positive. AcelRx Pharmaceuticals had 20 analyst reports since August 4, 2015 according to SRatingsIntel. The rating was maintained by H.C. Wainwright on Tuesday, May 3 with “Buy”. The firm has “Hold” rating by Piper Jaffray given on Tuesday, July 25. The rating was initiated by H.C. Wainwright with “Buy” on Wednesday, September 2. The stock of AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) has “Buy” rating given on Friday, May 6 by Seaport Global. The stock of AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) earned “Buy” rating by Jefferies on Friday, October 30. The stock of AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) has “Hold” rating given on Tuesday, August 1 by Cowen & Co. Jefferies maintained the shares of ACRX in report on Tuesday, November 14 with “Hold” rating. The rating was maintained by TH Capital with “Buy” on Monday, October 5. Jefferies maintained the shares of ACRX in report on Friday, July 14 with “Buy” rating. The rating was maintained by Roth Capital with “Buy” on Monday, October 5.

The stock decreased 0.33% or $0.3 during the last trading session, reaching $89.96. About 66,051 shares traded. Ingersoll-Rand Plc (NYSE:IR) has risen 39.42% since February 14, 2017 and is uptrending. It has outperformed by 22.72% the S&P500.

Investors sentiment increased to 1.16 in 2017 Q3. Its up 0.28, from 0.88 in 2017Q2. It increased, as 41 investors sold Ingersoll-Rand Plc shares while 190 reduced holdings. 77 funds opened positions while 191 raised stakes. 202.31 million shares or 0.64% more from 201.02 million shares in 2017Q2 were reported. Ibm Retirement Fund stated it has 0.11% in Ingersoll-Rand Plc (NYSE:IR). 9,688 were reported by Baldwin Brothers Ma. First Fincl Bank accumulated 0.17% or 11,385 shares. Johnson Gp holds 1,410 shares or 0.02% of its portfolio. Ubs Oconnor Limited Liability reported 198,120 shares. Credit Agricole S A holds 1.33 million shares or 0.41% of its portfolio. Tudor Corp Et Al has 0.02% invested in Ingersoll-Rand Plc (NYSE:IR) for 10,016 shares. Los Angeles Mgmt & Equity Research Inc reported 401,417 shares. Peapack Gladstone Fincl Corporation invested in 0.04% or 8,010 shares. Toronto Dominion National Bank & Trust has invested 0.03% of its portfolio in Ingersoll-Rand Plc (NYSE:IR). Howe And Rusling has invested 0.04% in Ingersoll-Rand Plc (NYSE:IR). Amer Century Companies Inc holds 0.36% of its portfolio in Ingersoll-Rand Plc (NYSE:IR) for 3.95 million shares. Lansdowne Prns (Uk) Ltd Liability Partnership invested in 32,530 shares or 0.03% of the stock. Peddock Cap Advsr Ltd Liability holds 4,950 shares. Da Davidson has 0.01% invested in Ingersoll-Rand Plc (NYSE:IR) for 6,750 shares.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.